Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Phenylacetate pharmacokinetics based on iterative two-stage population analysis.

Burstein AH, Reed E, Tompkins AC, Venzon D, Figg WD.

Pharmacotherapy. 2001 Mar;21(3):281-6.

PMID:
11253852
2.

Suramin-induced neutropenia.

Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, Figg WD.

Eur J Cancer. 1996 Aug;32A(9):1534-9.

PMID:
8911114
3.

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE.

Clin Cancer Res. 1996 Mar;2(3):483-91.

4.

Phase I study of phenylacetate administered twice daily to patients with cancer.

Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE.

Cancer. 1995 Jun 15;75(12):2932-8.

PMID:
7773944
5.

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, et al.

Cancer Res. 1994 Apr 1;54(7):1690-4.

Supplemental Content

Loading ...
Support Center